Actionable news
All posts from Actionable news
Actionable news in PFE: PFIZER Inc,

Pfizer: Good To Go


Pfizer recently settled a decade-long case relating to its older treatments Celebrex and Bextra.

Assuming Pfizer’s settlement is in the range of related past settlements, there should be no long-term impact.

Considering Pfizer’s high dividend yield, solid balance sheet and strong forward outlook, we believe that dividend-focused investors don’t need to wait until it reports its second quarter earnings before buying.


Pfizer Settles Celebrex and Bextra Lawsuits. Pfizer (NYSE:PFE) was in the news recently, finally settling a decade-long case relating to the cardiovascular risks associated with its blockbuster arthritis drugs Celebrex and Bextra. Terms were not disclosed but an earlier related settlement involving Bextra cost the...